ProUGN Biomarker Immunoassay for Early CKD Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for chronic kidney disease (CKD) are inadequate for early detection and staging, leading to low sensitivity and specificity, and lack reliable, non-invasive biomarkers for assessing renal function and dysfunction.
Innovation Solution
The use of prouroguanylin (proUGN) as a biomarker in biological fluids for diagnosing and monitoring renal dysfunction, with a method involving the measurement of proUGN levels and comparison to control reference ranges to determine kidney disease stages and treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods (serum creatinine, eGFR, albuminuria) are used for CKD detection, then the diagnostic process is simple and widely available, but the sensitivity and specificity for early detection are low
Solution Approach 1:
The patent introduces prouroguanylin (proUGN) as an intermediary biomarker that specifically reflects kidney dysfunction. proUGN is produced by kidney cells and its levels in biological fluids directly indicate renal function status, serving as a mediator between kidney health and detectable biomarker levels. This intermediary approach enables early detection with high sensitivity and specificity without requiring complex imaging or functional tests.
2Reliability
If early detection of kidney dysfunction is achieved through novel biomarkers, then diagnostic accuracy improves, but the complexity of the diagnostic method increases
Solution Approach 1:
The patent employs proUGN as a self-service biomarker that automatically reflects kidney function status without requiring external activation or complex processing. The biomarker is naturally produced by kidney cells and secreted into biological fluids, where it can be directly measured to indicate renal dysfunction. This self-service characteristic simplifies the diagnostic method while maintaining high reliability, as the biomarker inherently provides the diagnostic information needed.
3Productivity
If conventional biomarkers (creatinine, albumin) are used for monitoring kidney function, then the monitoring process is straightforward, but the ability to detect early-stage disease and stage progression is limited
Solution Approach 1:
The patent utilizes proUGN as a preliminary action biomarker that indicates kidney dysfunction before significant loss of renal function occurs. By measuring proUGN levels, the diagnostic system can identify early-stage disease and track progression through different CKD stages before conventional markers like creatinine and albumin show abnormalities. This preliminary detection capability enables earlier intervention and more effective disease management.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides high sensitivity and specificity for early diagnosis and staging of renal dysfunction, allowing for stage-specific clinical management and monitoring of treatment effectiveness, improving diagnostic efficiency and patient outcomes.
Implementation Method 1
a first proUGN antibody adhered to the surface; a second proUGN antibody comprising a detectable marker
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The levels of prouroguanylin (proUGN), or fragments thereof, present in blood are normally low in humans and are proposed to be involved in the physiologic regulation of oral and vascular salt levels in the body. When certain kidney related diseases or kidney dysfunctions occur, the level of proUGN or fragments thereof can rise dramatically and significantly. This rise of proUGN in the serum can be used as a marker to diagnose and, in turn, treat kidney disease, or monitor disease progression of kidney dysfunction, or can be used to predict the outcome of a treatment program for kidney disease and/or dysfunction. The level of proUGN or fragments thereof can be measured by a novel immunological assay, and a positive result above a cut-off value is diagnostic for chronic kidney disease (CKD). The calibration of that immunological assay can be done best by using a full-length appropriately folded and secreted recombinant human protein without any N'- or C' -terminal tags made in a human kidney cell line.